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In Brief
Hulea et al. investigate the mechanisms underlying the synergic efficacy of kinase inhibitors (KIs) and biguanides in targeting cancer cells and show that different pathways involving mTORC1, 4E-BP, and HIF-1a are at play. Cancer cells display metabolic plasticity by engaging non-redundant adaptive mechanisms, which allows them to survive therapy combinations.
INTRODUCTION
Metabolic perturbations in cancer are required to sustain neoplastic growth (Vander Heiden and DeBerardinis, 2017) . Metabolic differences between normal and cancer cells may provide a window to selectively target neoplasia (Vander Heiden and DeBerardinis, 2017) . The efficacy of clinically used kinase inhibitors (KIs) is associated with alterations in key metabolic pathways, including glycolysis (Poliaková et al., 2018) . Metformin (an anti-diabetic biguanide) induces energy stress via complex I inhibition and oxidative phosphorylation (OXPHOS) reduction (Andrzejewski et al., 2014; Bridges et al., 2014; Wheaton et al., 2014) , which leads to a compensatory increase in glycolysis (Javeshghani et al., 2012) . Biguanides exhibit antineoplastic effects in a variety of cancer models (DeBerardinis and . Phenformin is a more potent complex I inhibitor than metformin (Bridges et al., 2014) , and although it is associated with a higher risk of lactic acidosis than metformin, it is less toxic than many commonly used anti-cancer drugs.
Interventions that reduce glycolysis, including 2-DG (Ben Sahra et al., 2010) or glucose deprivation (Javeshghani et al., 2012) , sensitize cancer cells to biguanides. As KIs also reduce glycolysis (Pollak, 2013) , this provides a rationale for KI/biguanide combinations. Indeed, biguanides potentiate effects of BRAF and ERK inhibitors in melanoma (Trousil et al., 2017; Yuan et al., 2013) . However, the mechanisms that underpin anti-neoplastic effects of KI/biguanide combinations are largely unknown. Herein, metabolic perturbations driven by diverse oncogenic kinases were systematically probed with KI/phenformin combinations. This revealed that metabolic plasticity, whereby cancer cells engage multiple, non-overlapping metabolic adaptations in response to therapies, may limit responses.
RESULTS
Phenformin and KIs Exhibit Synergistic Effects across Different Cancer Cell Lines KI/biguanide combinations are effective in melanoma cells (Trousil et al., 2017; Yuan et al., 2013) . To establish the generality of these findings, we used KI/phenformin combinations in cancer cells of different origin: normal murine mammary gland (NMuMG) cells transformed with oncogenic Neu/ErbB2 (V664E) (NMuMG-NT2197, hereafter referred to as NT2197; Ursini-Siegel et al., 2008) , PLX4032-responsive BRAF-mutated A375 melanoma (Giard et al., 1973) , imatinib-responsive BCR-ABL-positive K562 myelogenous leukemia (Lozzio and Lozzio, 1975) , lapatinib-responsive VHL-deficient renal cancer RCC4 (Brodaczewska et al., 2016) , and HCT116 colorectal cancer (CRC) cells (Brattain et al., 1981) .
Lapatinib is a dual HER2/epidermal growth factor receptor (EGFR) inhibitor approved for treatment of HER2-amplified BCa (Geyer et al., 2006) . NT2197 ErbB2-driven BCa cells were treated with increasing concentrations of lapatinib, phenformin, or combinations thereof. A concentration of phenformin (100 mM) that only marginally inhibited proliferation sensitized NT2197 cells to lapatinib (Figures 1A and S1A-S1C), whereas low concentrations of lapatinib (75 nM) increased the anti-proliferative effects of phenformin (Figures S1D and S1E) . At these concentrations, the phenformin/lapatinib combination exerted only minor effects on proliferation of non-malignant cells, including parental, non-transformed NMuMG cells, mouse embryonic (MEFs), or lung fibroblasts (IMR90), which express EGFR, but in which HER2 is not amplified (Figures 1A and S1F-S1J). We next determined the combination index (CI50; Tallarida, 2006) of the lapatinib/phenformin interaction, which revealed synergistic anti-proliferative effects (CI50 $0.8; Figures  1B and S1K) . Accordingly, when combined, these drugs decreased the survival of NT2197 cells to a much greater extent than either drug alone ( Figure S1L) . Parallel results were observed in all the cancer cell lines tested, indicating that KIs and phenformin synergize independently of the type of the driving oncogene and cancer origin ( Figures 1C-1E , S1M-S1R, and S2A-S2G).
To establish whether, as reported for melanoma (Yuan et al., 2013) , these effects also occur in vivo, we employed NT2197 xenograft model . Consistent with cell culture observations, single drugs only modestly inhibited tumor growth ($20% of control), whereas their combination resulted in a more potent anti-neoplastic effect ($50% of control, p = 0.0002) ( Figure 1F ). Tumors were not eradicated, which is explained by the aggressive nature of the model . The anti-proliferative effects of lapatinib were potentiated by phenformin ( Figures 1G, S2H , and S2I). Of note, the absolute number of apoptotic cells in tumors was lower than in cell culture, consistent with efficient removal of apoptotic cells by phagocytes in vivo (Poon et al., 2014) and lower achievable concentration of phenformin in plasma ($2 mM) and tissues ($1 mM) (Table S1 ) versus cell culture ($100-250 mM). Thus, phenformin-induced enhancement of anti-tumor efficacy of KIs in vivo is not confined to melanoma models.
KIs and Biguanides Have Distinct Effects on Cancer Metabolome
We next sought to identify metabolic pathways that underlie lapatinib/phenformin synergy. The lapatinib/phenformin combination, but not each drug alone, significantly reduced ATP levels in NT2197 cells ( Figure S2J ). As expected, phenformin increased lactate while strongly decreasing citrate and succinate levels, which reflects reduced CAC activity due to complex I inhibition and compensatory increase in glycolysis ( Figure 2A ) Javeshghani et al., 2012) . In contrast, lapatinib reduced lactate levels, in agreement with previous observations that KIs suppress glycolysis (Pollak, 2013) and decrease 18 F-fludeoxyglucose (FDG) uptake in patients (McArthur et al., 2012) . Lapatinib and phenformin exhibited opposite effects on the CAC intermediates fumarate, malate, citrate, and a-ketoglutarate (a-KG), suggesting that KIs may impede biguanide-induced metabolic adaptations ( Figure 2A ). Indeed, KIs attenuated phenformin-induced alterations of these CAC intermediates (Figure 2A) and aspartate (Figures 2A and S2K) . In turn, lapatinib and phenformin increased serine, glycine, and proline, while reducing methionine levels (Figure 2A , lower panel). Glucose uptake and the lactate/pyruvate ratio were increased by phenformin and reduced by lapatinib ( Figures 2B and 2C ). These findings demonstrate that lapatinib opposes the phenformin-induced increase in glycolysis. Accordingly, pyruvate supplementation decreased the anti-proliferative effects of lapatinib/phenformin combination ( Figure S2L) .
Phenformin also increased a-KG/citrate ratio ( Figure 2D ), which is associated with induction of reductive glutamine metabolism that allows the synthesis of CAC intermediates for biosynthetic pathways, including lipogenesis, and is implicated in maintaining REDOX homeostasis when OXPHOS is inhibited Jiang et al., 2016; Mullen et al., 2011) . Lapatinib suppressed the phenformin-induced increase in the a-KG/citrate ratio ( Figure 2D ). 13 C 5 -glutamine tracing experiments confirmed that phenformin induces reductive glutamine metabolism as evidenced by enrichment in malate and fumarate (m+3) isotopomers, relative to the control, which was abrogated by lapatinib (Figures 2E and S2M) . Comparable effects of the KI/phenformin combinations on glucose uptake, and the lactate/pyruvate and a-KG/citrate ratios, were observed across all cancer cell lines ( Figures 2F-2H and S2N ). These data suggest that KIs may hinder metabolic adaptations to (B) Combination index 50 (CI 50 ) for lapatinib and phenformin was determined by isobologram method (corresponding proliferation curves are shown in A and Figures S1C-S1E).
(C-E) A375 (C), K562 (D), and HCT116 (E) cells were treated with phenformin and/or PLX4032 (C), imatinib (D), or lapatinib (E), as indicated for 72 hr. Proliferation was estimated by BrdU incorporation. PLX4032 (C), imatinib (D), or lapatinib (E) interactions with phenformin were evaluated by the isobologram method.
Corresponding proliferation curves are shown in Figures S1M-S1R, S2A, and S2B, and F and G. In (A)-(E), the data are presented as means ± SD (three independent experiments, three technical replicates averaged in each). (F and G) A total of 50,000 NT2197 cells were injected into two mammary fat pads of Nu/Nu mice. When tumors reached 100-200 mm 3 , mice were randomly distributed into 4 groups of 5 mice and treated with phenformin (50 mg/kg), lapatinib (50 mg/kg), or both every 24 hr for 8 days. (F) Tumor growth was measured as described every 2 days until the control tumors reached 500 mm 3 . The data are presented as means ± SEM (n = 10 tumors) (*p < 0.05, **p < 0.01, and ***p < 0.001, two-way ANOVA). Mice were sacrificed on day 8, 4 hr after the last treatment. (G) Tumor sections from seven tumors/group were stained with Ki67 antibody. (**p < 0.001, ANOVA). Representative images are shown in Figure S2I . See also Figures S1 and S2. phenformin-induced energy stress by interfering with the reductive glutamine metabolism. Accordingly, depletion of isocitrate dehydrogenase 1 (IDH1), a rate-limiting reductive glutamine metabolism enzyme, potentiated the effects of the drug combination ( Figure S2O ).
Similar to the effects observed in tissue culture, phenformin increased lactate production and decreased citrate levels in vivo as compared to the control, whereas these effects were attenuated by lapatinib ( Figure S2P ). The magnitude of the in vivo effects was less than that in cell culture. This is consistent with lower achievable concentrations of phenformin in vivo as compared to cell culture (Table S1 ) and the presence of noncancerous cells in tumors (e.g., fibroblasts), which are expected to be less affected by drugs (as shown for non-transformed cells in Figures 1A and S1F-S1J). Phenformin also increased glutamine levels in the tumors as compared to control and lapatinib ( Figure S2P ). In cell culture, observed responses to KIs and biguanides were associated with changes in glutamine metabolism; however, the role of glutamine utilization in vivo has been questioned (Davidson et al., 2016) . To address this, mice bearing tumors were infused with 13 C 5 -glutamine (2 hr), leading to $35% 13 C-labeled/total glutamine pool in tumors ( Figures  S2Q, S3A , and S3B). The metabolites derived from glutamine (glutamate, a-KG, citrate, malate, and succinate) incorporated 13 C at a considerable proportion of total pool ($20%-26%) (Figures S2Q, S3A, and S3B) . Indeed, out of the total 13 C 5 -glutamine-labeled carbons present in the tumors, 79% 13 C were incorporated into glutamate, $81% into citrate, $67% into a-KG, and $62% into malate and succinate, indicating that glutamine is an important anaplerotic source for CAC in NT2197 model.
Opposing Effects of Lapatinib and Phenformin on
Glycolysis Are Insufficient to Explain Their Synergy Suppression of the compensatory increase in glycolysis induced by biguanides has been reported to result in cell death (Ben Sahra et al., 2010) . It is therefore plausible that lapatinib synergizes with phenformin by suppressing glucose uptake and/or glycolysis. We thus investigated the effects of combining phenformin with 3PO, which inhibits 6-phosphofructo-2-kinase/fruc-tose-2,6-bisphosphatase 3 (PFKFB3) (Clem et al., 2008) . 3PO was used instead of more potent glycolytic inhibitors (e.g., 2-DG) to induce a comparable suppression of glucose uptake and lactate production as lapatinib ($30%; Figures 2I, S3C, and S3D) . Surprisingly, a 3PO concentration that inhibited glycolysis to a level comparable to lapatinib failed to synergize with phenformin ( Figures 1B, 2J , S3E, and S3F). This suggests that lapatinib-induced inhibition of glycolysis cannot fully explain the lapatinib/phenformin synergy.
KIs and Biguanides Suppress Protein Synthesis and Cooperatively Downregulate mTORC1
Oncogenic kinases alter mRNA translation (Bhat et al., 2015) . Since translation is highly energy demanding (Buttgereit and Brand, 1995) , cancer cells must balance ATP production with translation rates . Indeed, sustained translation in energy-deficient cells is deleterious (Leprivier et al., 2013) . Phenformin (250 mM) suppressed translation more strongly than lapatinib (600 nM) as illustrated by reduced polysome/monosome ratio and lower puromycilation (Figures S3G-S3I). The drug combination only marginally reduced translation as compared to phenformin alone ( Figures S3G-S3I ). This diminishes the plausibility that lapatinib/phenformin synergy is caused by energy depletion induced by sustained translation when ATP is limited.
The mechanistic/mammalian target of rapamycin complex 1 (mTORC1) stimulates translation (Bhat et al., 2015) . Both lapatinib and phenformin inhibit mTORC1 (Bhat et al., 2015) . We therefore determined the effects of lapatinib, phenformin, or combination thereof on mTORC1 signaling in NT2197 cells. Lapatinib (600 nM) abolished the MAPK/ERK signaling as evidenced by reduction in ERK1/2 phosphorylation relative to control, and suppressed mTORC1 as illustrated by decreased phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and the ribosomal protein S6 kinases 1 and 2 (S6K1/2), as well as ribosomal protein S6 (rpS6) ( Figure 3A ) (Bhat et al., 2015) . Phenformin (250 mM) induced AMP-activated protein kinase (AMPK) and its downstream substrate acetyl-CoA carboxylase (ACC) (Munday, 2002) (Figure 3A) . When the drugs were combined at concentrations (A) Levels of indicated metabolites in NT2197 cells treated for 24 hr with phenformin (600 mM), lapatinib (600 nM), or combination thereof were determined by gas chromatography-mass spectrometry (GC-MS). Data are shown as mean ± SD. *p < 0.05 (two-way ANOVA; two independent experiments, three technical replicates averaged in each). (B-D) NT2197 cells were treated with vehicle (DMSO), phenformin (250 mM), and/or lapatinib (600 nM) for 24 hr. (B) Glucose uptake was monitored by subtracting glucose concentration in media with cells versus cell-free media and normalized to DMSO control. Data are shown as mean ± SD. **p < 0.01 (two-way ANOVA; two independent experiments, three technical replicates averaged in each). (C and D) Intracellular lactate/pyruvate (C) and a-KG/citrate ratios (D) were determined by GC-MS and normalized to control. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 (two-way ANOVA; two independent experiments, three technical replicates averaged in each). (E) NT2197 cells were treated as in (B)-(D) for 24 hr and incubated with 13 C 5 -glutamine. Absolute malate (m+3) ion levels are shown. Data are representative of two independent experiments. AU, arbitrary units. Right: schematic of the 13 C incorporation into metabolites. (F-H) A375 cells were treated with phenformin (1.5 mM) and/or PLX4032 (200 nM) for 24 hr. (F) Glucose uptake was normalized to DMSO control. Data are shown as mean ± SD. *p < 0.05 (two-way ANOVA; three independent experiments, three averaged technical replicates each). (G and H) Intracellular lactate/pyruvate (G) and a-KG/citrate (H) ratio. Metabolites were measured by GC-MS and normalized to DMSO control. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 (two-way ANOVA; two independent experiments, three technical replicates averaged in each). (I) NT2197 cells treated with vehicle (DMSO), 3-PO (15 mM), or lapatinib (300 nM) for 24 hr were incubated with 13 C 6 -glucose for 90 min. Absolute lactate (m+3) ion amounts are shown, normalized to control. Data are shown as mean ± SD from three independent experiments. (J) NT2197 cells were treated as indicated for 72 hr. Proliferation was monitored by BrdU incorporation and expressed as percentage of non-phenformin treated cells. The data are presented as mean ± SD (two independent experiments, three technical replicates averaged in each). See also Figures S2 and S3 . that result in synergistic effects, mTORC1 was suppressed to a higher extent relative to each drug alone (Figures 3A and S3J) . Similar effects of KI/phenformin combinations on signaling were observed in vivo ( Figure S3K ) and other cancer types (Figures 3B and 3C) .
The phenformin/lapatinib combination suppressed mTORC1 and translation to a lesser extent than mTOR inhibitor torin1 (Figures S3I and S3L) . The moderate mTORC1 inhibition by the phenformin/lapatinib combination, however, was associated with a pronounced pro-apoptotic effect, whereas almost complete obliteration of mTORC1 signaling with torin1 led to a mostly cytostatic effect ( Figure S1L ). This is consistent with the tenet that potent mTOR inhibitors (e.g., torin1) induce metabolic dormancy, where suppression of ATP production is compensated by reduction in translation and other anabolic processes, thus leading to reduced ATP consumption (Gandin et al., 2016b; Morita et al., 2013) . Phenformin/lapatinib synergy is therefore not attributable solely to mTORC1 inhibition, but it appears to be mediated by moderate mTORC1 suppression in concert with metabolic stress. eIF2a phosphorylation leads to reduced protein synthesis (Ron and Harding, 2007) . Phenformin, but not lapatinib, stimulated eIF2a phosphorylation ( Figure 3A) , consistent with the more pronounced inhibition of global translation by phenformin than lapatinib ( Figures S3G-S3I ). Thus, in addition to their opposing effects on glycolysis and reductive glutamine metabolism, lapatinib and phenformin cooperatively suppress mTORC1, which, in addition to the induction of eIF2a phosphorylation by phenformin, results in decreased protein synthesis.
4E-BPs Are Essential for Synergistic Effects of KI and Biguanides
In addition to regulating global translation, mTOR selectively perturbs the translatome (Bhat et al., 2015) . This is in part mediated by the effects of mTORC1 on 4E-BPs and, consequently, on the eIF4F complex assembly (Bhat et al., 2015) . KI/phenformin combination reduced the levels of proteins encoded by mRNAs previously demonstrated to be ''eIF4F-sensitive'' more dramatically than either drug alone. These included anti-apoptotic proteins (survivin, MCL-1, and BCL-2), oncogenes (c-MYC), and factors with mitochondrial functions (TFAM), but not those whose expression is less ''eIF4F-sensitive'' (b-actin, GAPDH, GOT1, or eIF4E; Figures 3B-3E ).
To investigate whether the mTORC1/4E-BP/eIF4F axis contributes to lapatinib/phenformin synergy, we generated NT2197 cells that lack 4E-BP1 and 2 by CRISPR/Cas9 (Figure 4A ). 4E-BP1/2 loss decreased the anti-proliferative and pro-apoptotic effects of the lapatinib/phenformin combination relative to 4E-BP1/2-proficient cells ( Figures 4B, 4C , and S4A-S4I) or 4E-BP1/2-deficient cells in which 4E-BP1 was re-expressed ( Figures S4J and S4K ). 4E-BP1/2 loss also negated the effects of the drug combination on the eIF4F complex assembly ( Figures 4D, 4E , S4L, and S5A; Data S1). This was paral-leled by diminished effects of the drugs on the levels of proteins encoded by ''eIF4F-sensitive'' mRNAs ( Figure 4F ). The loss of 4E-BP1/2 also attenuated the anti-proliferative effects of the PLX4032/phenformin combination in A375 cells ( Figures S4M  and S4N ). These findings show that 4E-BPs are critical for KI/biguanide synergy.
The mTORC1/4E-BP Axis Regulates Translation of mRNAs Encoding Rate-Limiting Enzymes of Metabolic Pathways that Fuel Neoplastic Growth, Including NEAA Synthesis Serine, aspartate, and asparagine biosynthesis pathways are implicated in mTOR-driven oncogenesis (DeBerardinis and Vander Heiden and DeBerardinis, 2017) . Relative to single drugs, KI/phenformin combinations decreased levels of proteins that play key roles in these metabolic pathways, including phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), pyruvate carboxylase (PC), and asparagine synthetase (ASNS), but not glutamic-oxaloacetic transaminase 1 (GOT1) ( Figures 3B-3E, and S4N ). Ablation of 4E-BP1/2 abolished the effects of drug combinations on the expression of these proteins ( Figures 4F and S4N ).
We next assessed whether the observed effects of the lapatinib/phenformin combination occur at the level of translation by polysome profiling ) ( Figure 5A ). In NT2197 cells, under basal conditions, Phgdh, Psat1, Pc, and Asns mRNAs are translated at high efficiency as illustrated by their distribution within the heavy polysome fractions ( Figure 5B ). The lapatinib/phenformin combination reduced translation of Phgdh, Psat1, Pc, and Asns mRNAs in 4E-BP1/2 proficient, but not deficient, cells, as evidenced by their shift toward the fractions with less ribosomes ( Figure 5B ). A similar trend was observed for Ccnd3 mRNA, which is regulated via the mTORC1/4E-BP pathway (Larsson et al., 2012) . In contrast, lapatinib and phenformin only marginally affected translation of ''eIF4F-insensitive'' Actb, Gapdh, or Got1 mRNAs ( Figure 5B ). These changes were not accompanied by changes in Phgdh, Psat1, and Asns mRNA levels, whereas Pc mRNA was slightly increased in 4E-BP1/2-deficient versus -proficient cells ( Figures  S5B and S5C) . These data demonstrate that the mTORC1/4E-BP-dependent translation control may play a role in serine, aspartate, and asparagine synthesis.
Metabolic Reprogramming Caused by 4E-BP1/2 Loss Decreases the Efficacy of the KI/Biguanide Combinations 4E-BP1/2 status in the cells determines translation of mRNAs encoding proteins that play critical roles in aspartate, asparagine, and serine synthesis ( Figure 5B ) and mitochondrial functions (Gandin et al., 2016b; Morita et al., 2013) . Accordingly, amino acids, including aspartate, asparagine, serine, and alanine, as well as CAC intermediates (e.g., malate, fumarate, and succinate) and pyruvate, were elevated in Tukey test from ten different fields). Representative images are shown in Figure S5A and Data S1. (E) Amounts of the indicated proteins in the input or pull-down were determined by western blot; b-actin was a loading control (input) and was used to exclude contamination (m 7 GDP pull-down). (F) CTR or 4E-BP DKO cl17 cells were treated as shown. The expression of indicated proteins was determined by western blot. b-actin was a loading control. (E and F) Experiments are representative of two independent replicates. See also Figures S4 and S5 . 4E-BP1/2-deficient versus -proficient cells ( Figures 6A and S5D) . Combining phenformin and lapatinib altered the levels of these metabolites in both control and 4E-BP1/2 NT2197 knockout (KO) cells, but their abundance remained significantly higher in cells lacking 4E-BP1/2 ( Figures 6A and S5D ).
Aspartate and serine synthesis are involved in nucleotide and protein synthesis and other processes required for proliferation (Vander Heiden and DeBerardinis, 2017) . To identify metabolic pathways responsible for the increase in aspartate in 4E-BP1/2 ablated cells, we performed 13 C 6 -glucose tracing. 4E-BP1/2 loss increased the proportion of m+3 aspartate, malate, and fumarate, as compared to control ( Figure S5E ), as well as the absolute amount of m+3 aspartate and malate ( Figures 6B and  S6A) . Thus, cells lacking 4E-BP1/2 maintain high aspartate levels by using pyruvate to generate malate and aspartate via oxaloacetate ( Figures S5E and S6A) , which is consistent with elevated PC levels ( Figure 4F ). This finding was confirmed by higher 3-13 C-glucose-derived m+1 aspartate levels in 4E-BP1/2depleted versus control cells ( Figure S6B ). Importantly, 10 mM aspartate decreased sensitivity of control cells to the drug combination ( Figure 6C ), whereas it only marginally influenced the drug efficacy in 4E-BP1/2-deficient cells in which aspartate levels are already high ( Figure S6C ). Aspartate is essential for de novo synthesis of asparagine, which is catalyzed by asparagine synthetase (ASNS) that simultaneously converts glutamine to glutamate (Balasubramanian et al., 2013) . Consistent with mTORC1/4E-BP-dependent regulation of ASNS (Figures 3D,  4F , and 5B), cells lacking 4E-BP1/2 exhibit higher asparagine and glutamate levels than control cells ( Figure 6A ). Asparagine also alleviated the anti-proliferative effects of the drug combination in 4E-BP1/2-proficient cells ( Figure 6D ). This suggests that the effects of aspartate may be mediated by its conversion to asparagine. Indeed, ASNS depletion increased the phenformin/lapatinib combination efficacy ( Figures S6D-S6F ). Finally, A B Figure 5 . Phenformin/Lapatinib Combination Suppresses Translation of mRNAs that Encode NEAA Biosynthetic Enzymes (A) CTR or 4E-BP DKO cl17 NT2197 cells were treated with vehicle (DMSO) or combination of phenformin (250 mM) and lapatinib (600 nM) for 4 hr. Sub-polysomal, light-, and heavy-polysome fractions were obtained by ultracentrifugation using 5%-50% sucrose gradients. Positions of 40S and 60S ribosomal subunits, monosome (80S), and polysomes in the absorbance profiles (254 nm) are shown. (B) Amount of indicated mRNAs in polysome fractions was determined by qRT-PCR (as described; Miloslavski et al., 2014) . Corresponding total mRNA levels are shown in Figures S5B and S5C . Data are representative of three independent experiments (three technical replicates each) and are expressed as a percentage of mRNA in each fraction ± SD. See also Figure S5 . depletion of asparagine from media by L-asparaginase potentiated effects of phenformin/lapatinib combination to a greater extent in 4E-BP-proficient than 4E-BP-deficient cells (Figure S6G) . Serine levels and the proportion of m+3 serine derived from 13 C 6 -glucose are higher in 4E-BP-deficient versus -proficient cells (Figures 6A, 6B, and S5E) , which is consistent with 4E-BP-mediated effects of the drug combination on PHGDH and PSAT1 levels. Serine has been shown to influence sensitivity to biguanides . Accordingly, depletion of PHGDH in 4E-BP1/2-deficient cells increased drug combination efficacy ( Figures S6H-S6J ). Thus, mTORC1/4E-BP-mediated effects on aspartate, asparagine, and serine biosynthesis determine the efficacy of the KI/biguanide combinations.
HIF-1a Influences Sensitivity to Lapatinib and Phenformin
HIF-1a is upregulated in HER2 overexpressing cells (Schito and Rey, 2017) . In NT2197 cells, the phenformin/lapatinib combination more strongly decreased HIF-1a than single drugs (Figure 3D) , which was paralleled by the reduction of HIF-1a target (legend continued on next page) genes ( Figure S6K ). Of note, Vegfa, Glut1, and Hk2 mRNAs were decreased by lapatinib alone (Figure S6K ), which is consistent with previous observations (Acharya et al., 2016; Le et al., 2008; Liu et al., 2016) . In turn, HIF-2a was undetectable under normoxic conditions ( Figure S6L ), which can be explained by differential regulation of HIF-1a and 2a by HER2 (Whelan et al., 2013) . mTOR regulates HIF-1a by multiple mechanisms including via 4E-BPs (Dodd et al., 2015) . In NT2197 cells, however, HIF-1a does not appear to be regulated by 4E-BPs ( Figure 4F ). E3 ubiquitin ligase VHL regulates expression of HIFs by degrading them under normoxia (Semenza, 2007) . RCC4 renal carcinoma cells lack VHL and express high levels of HIF-1a (Maxwell et al., 1999) . Notably, lapatinib has been used in renal cancer clinical trials (Ravaud et al., 2008) . The lapatinib/phenformin combination reduced HIF-1a in VHL-reconstituted (RCC4-VHL), but not VHL null, RCC4 cells (RCC4-mock) ( Figure 7A ). This effect was abolished by hypoxia-mimetic CoCl 2 ( Figure S6M ). VHL status did not influence the effects of the drugs on mTORC1 ( Figure 7A) . Thus, the lapatinib/phenformin combination reduces HIF-1a levels in RCC4 cells in a VHL-dependent manner. Accordingly, the anti-proliferative effect of the drug combination was less pronounced in RCC4-mock versus RCC4-VHL cells (Figures 7B and  S7A ). This suggests that downregulation of HIF-1a critically contributes to lapatinib/biguanide synergy. Indeed, stabilization of HIF-1a with dimethyloxallyl glycine (DMOG) (Cummins et al., 2008) decreased sensitivity of the RCC4-VHL cells to the drug combination ( Figures S7B and S7C) . Notwithstanding that DMOG concentrations used for acute HIF-1a stabilization range between 250 and 1,000 mM (Heir et al., 2016) , for the proliferation assay we used 25 mM DMOG, which is sufficient to stabilize HIF-1a levels without toxicity during a 72 hr treatment ( Figures  S7B and S7C ).
Phenformin induced glycolysis in both RCC4-mock and RCC4-VHL cells, as monitored by the lactate/pyruvate ratio; however, the magnitude of the effects was greater in RCC4-VHL cells, and this was impeded by lapatinib ( Figure S7D ). Loss of VHL triggers reductive glutamine metabolism (Gameiro et al., 2013) , which was confirmed by 13 C 5 -glutamine tracing that revealed higher levels of citrate (m+5), malate (m+3), and aspartate (m+3) isotopomers in RCC4-mock versus RCC4-VHL cells (Figures 7C and S7E) . Conversely, lower levels of oxidative glutamine metabolism-derived fumarate (m+4), malate (m+4), aspartate (m+4), and citrate (m+4) isotopomers were observed in RCC4-mock versus RCC4-VHL cells ( Figure 7C) . These findings suggest that HIF-1a-dependent regulation of reductive glutamine metabolism determines the effects of phenformin/ lapatinib combination ( Figure 7D ). We therefore induced HIF-1a levels in RCC4-VHL cells with DMOG ( Figure S7C ) followed by 13 C 5 -glutamine tracing. DMOG increased markers of reductive (citrate m+5, isocitrate m+5), while decreasing oxidative (citrate m+4, isocitrate m+4) glutamine metabolism intermediates, relative to vehicle-treated cells ( Figure S7F ). Since DMOG may induce metabolic effects before affecting HIF-1a levels (Zhdanov et al., 2015) , we depleted HIF-1a in RCC4-mock cells, which resulted in an increase in oxidative and a decline in reductive glutamine metabolism (Figures S7G and S7H) . Consistently, viability of RCC4-mock cells was decreased upon suppression of reductive glutamine metabolism by IDH1 depletion, which was further potentiated by the drug combination ( Figure S7I ). Untreated RCC4-VHL cells were only marginally affected by IDH1 depletion, which is in accordance with their preference for oxidative glutamine metabolism. In contrast, the effects of the phenformin/lapatinib combination on viability were potentiated by IDH1 depletion in RCC4-VHL cells ( Figure S7I ). HIF-1a negatively affects mitochondrial enzyme complex a-ketoglutarate dehydrogenase (aKGDH) subunit E1 (OGDH) (Sun and Denko, 2014) . OGDH catalyzes the oxidative decarboxylation of a-KG to succinyl-CoA. At baseline, OGDH levels were lower in VHL-deficient versus -proficient RCC4 cells ( Figure S7J ), which was mirrored by alterations in the 13 C 5 -glutamine-derived succinate (m+4) ( Figures 7C and 7D) . Moreover, the phenformin/lapatinib combination decreased OGDH levels in VHL-proficient, but not -deficient, cells ( Figure S7J) , which is consistent with the drugs acting via HIF-1a. HIF-2a levels were higher in RCC4-mock as compared to RCC4-VHL cells, but HIF-2a protein levels were not affected by drugs ( Figure S7K ). These findings demonstrate that HIF-1a-dependent modulation of glutamine metabolism is a critical determinant of the efficacy of KI/biguanide combinations.
DISCUSSION
It has been proposed that biguanides may improve KI efficacy. Preclinical studies suggest that biguanides enhance activity of trastuzumab, BRAF, and ERK inhibitors (Trousil et al., 2017; Vazquez-Martin et al., 2011; Yuan et al., 2013) . Although these findings are being evaluated in clinical trials, the underlying mechanisms are not fully understood. We show that KIs synergize with biguanides in cancer cell types that differ in their origin and the driving oncogenic kinase. KIs attenuate the biguanideinduced increase in glycolysis, which was considered as a plausible mechanism to account for the synergy between the drugs. However, our data show that this simple model is insufficient to explain KI/biguanide synergy. We show that metabolic and translational perturbation mediated via the mTORC1/4E-BP1 axis and HIF-1a critically contribute to the efficacy of KI/biguanide combinations.
Aspartate has been identified as a key metabolite required for neoplastic growth (Vander Heiden and DeBerardinis, 2017) . Aspartate can be generated from pyruvate via PC, which converts pyruvate to oxaloacetate (Ling and Keech, 1966) . Elevated PC expression and/or activity is observed in breast cancer and non-small-cell lung cancer (Phannasil et al., 2017; Sellers et al., 2015) . We show that Pc mRNA translation is regulated via 4E-BPs and that 4E-BP1/2 ablation leads to dramatic increase in aspartate levels and reduction in sensitivity to the KI/phenformin (C) Cells described in (A) were incubated with 13 C 5 -glutamine for 30 min, 1 hr, and 2 hr. Stable isotope tracer analysis was performed, and the levels of the indicated ion amounts (fraction of the total pool) are shown. Data are representative of two independent experiments. Bottom right panel: schematic of the 13 C incorporation into metabolites. For additional data, see Figure S7E . (D) Schematic showing the utilization for glutamine in RCC4 cells depending on VHL status/HIF-1a levels. See also Figures S6 and S7. combination. GOT1 is required for aspartate synthesis under electron transport chain deficiency (Birsoy et al., 2015) . The phenformin/lapatinib combination does not alter GOT1 ( Figures  3D and 5B ), suggesting the existence of an alternative mechanism whereby aspartate levels are influenced through the action of PC. Furthermore, aspartate conversion to asparagine, which is regulated by 4E-BP-dependent translation of Asns mRNA, appears to play a major role in the phenformin/KI synergy. Accordingly, L-asparaginase, which depletes asparagine pools, is used in treating low-ASNS-expressing acute lymphoblastic leukemia and pediatric acute myeloid leukemia (Hill et al., 1967) . ASNS is also required for KRAS-driven oncogenesis (Gwinn et al., 2018) ; glioma, neuroblastoma, and mouse sarcoma growth (Hettmer et al., 2015; Zhang et al., 2014) ; and breast cancer metastasis (Knott et al., 2018) .
Cancer cells exhibit increased serine biosynthesis (Snell, 1984) . PHGDH and PSAT1 are overexpressed in subtypes of breast cancer, melanoma, cervical cancer, and glioma (DeBerardinis and and are linked to poor prognosis in lung cancers (DeNicola et al., 2015; Zhang et al., 2017) . Increase in serine synthesis appears to be beneficial for cancer cells irrespective of the availability of serine in the environment, or intracellular serine levels (Mattaini et al., 2016) . This is explained by serine being a central node for the biosynthesis of many metabolites (e.g., nucleotides, folate metabolism), amino acid transport, and redox homeostasis (DeBerardinis and . Accordingly, we show that 4E-BP-dependent translational regulation of serine synthesis is a critical determinant of sensitivity of cancer cells to KI/biguanide combinations.
We also provide evidence suggesting that HIF-1a-dependent modulation of glutamine metabolism underpins the KI/phenformin synergy. HER2 upregulates HIF-1a, even under normoxic conditions (Semenza, 2013) , which is required for neoplastic growth (Whelan et al., 2013) . KI/biguanide combinations appear to downregulate HIF-1a via VHL, which is in accordance with reports showing that metformin induces HIF-1a degradation through inhibition of mitochondrial complex I (Wheaton et al., 2014) . RCC4 cells that lack VHL and thus exhibit high HIF-1a are less sensitive to the KI/biguanide combination, which coincides with increased reductive glutamine metabolism (Sun and Denko, 2014) . These data suggest that VHL loss and/or HIF-1a activation decreases the efficacy of KI/biguanide combinations. Therefore, the mTORC1/4E-BP and VHL/HIF-1a axes constitute two independent mechanisms that allow metabolic adaptations to KI/biguanide combinations.
Strong mTOR inhibition is associated with metabolic dormancy and cytostatic effects (Gandin et al., 2016b; Morita et al., 2013) . In stark contrast, KI/biguanide combinations, although inducing considerably less inhibition of mTOR, result in cell death. Our findings therefore suggest that mild mTOR inhibition, which is sufficient to induce translational reprogramming of the metabolome, but not to decrease energy consumption, is more likely to lead to an energetic crisis and cell death than more potent mTOR inhibition. This suggests that targeting oncogenic mTOR signaling with combinations of upstream KIs and biguanides may be an alternative to mTOR inhibitors. However, it is important to note that early results of clinical trials employing biguanides in oncology have been disappointing (Kordes et al., 2015) . One reason for this may relate to sub-optimal pharmacokinetics of metformin Dowling et al., 2016) , an issue that may be addressed by the use of novel biguanides or other OXPHOS inhibitors (Molina et al., 2018; Zhang et al., 2016) . Other trials, including one using phenformin in combination with BRAF inhibitors, are underway (https:// clinicaltrials.gov/; NCT03026517). Our study shows that metabolic adaptations that underpin plasticity of cancer cells should also be considered as a factor explaining the potential limited clinical efficacy of biguanides, including KI/biguanide combinations.
In conclusion, we show that 4E-BP-dependent translational regulation of NEAA synthesis, in combination with HIF-1a-dependent alterations in glutamine metabolism, determines the efficacy of KI/biguanide combinations. This suggests that the outcomes of drug-induced energy stress depend on the ability of cancer cells to engage multiple pathways that underlie metabolic adaptations. Indeed, metabolic plasticity is emerging as a major factor in resistance to cancer treatments (Boudreau et al., 2016; Krstic et al., 2017; Lehué dé et al., 2016) . Metabolic plasticity thus represents a paramount challenge, as genetic and/or epigenetic alterations, including those affecting 4E-BP and HIF-1a function, enable cancer cells to evade metabolic stresses and hinder efficacy of metabolome-focused cancer therapies. This suggests that further research should focus on identifying specific targets for which metabolic plasticity would have limited potential of attenuating drug efficacy.
Limitations of Study
This study unraveled the mechanisms of synergy between KIs and biguanides and identified metabolic plasticity as a major factor that determines their efficacy. Nonetheless, in vivo studies in relevant pre-clinical models are required to provide more clinical relevance (e.g., addressing issues related to pharmacokinetics and pharmacodynamics of the KI/biguanide combinations). Moreover, systems biology approaches are warranted to capture the full complexity of perturbations in gene expression and signaling networks that underpin the metabolic adaptability of tumors to therapeutic insults. Finally, future research is needed to determine the mechanisms of metabolic plasticity of neoplasia at the organismal level.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Puromycilation Assay NT2197 cells were maintained in puromycin free media for 48h. Then, cells were seeded in 100mm dishes for 24h, followed by 4h treatment as indicated in Figure S3I . During the last 15 min of treatment, puromycin (10 mg/mL) was added to the media. Cell lysates and western blot procedure were done as described in the ''Western blotting and antibodies'' section. Quantification of band intensities was done using ImageJ software (https://imagej.nih.gov/ij/index.html). Quantification was performed from 3 independent experiments and data was expressed as average ± SD of the reduction in puromycilation levels relative to DMSO control.
Glucose Consumption and Lactate Release Assays NT2197 and A375 cells were seeded in 6-well plates and cultured in complete medium for 24h in order to obtain 30% density. Medium was replaced with 2ml of indicated treatment media, and cells were cultured for 22h. Treatment media was replaced with 0.7 to 1 mL of fresh treatment media for an additional 4h. Subsequently, supernatant samples were collected and cells were counted using an automated cell counter (Invitrogen). For K562, cells were seeded in 6-well plates and cultured in treatment media for 24h. Subsequently, supernatant samples were collected and cells were counted using an automated cell counter (Invitrogen). Measurement of glucose concentration in samples was done as previously described . Total consumption was calculated by subtracting results from baseline glucose concentration, measured in samples from media incubated in identical conditions, without cells. Molar concentrations of glucose were multiplied by total media volume/well (0.7 to 1ml) and normalized per 10 6 cells; data were expressed as mM glucose/10 6 cells/h, or normalized relative to DMSO control. Lactate release was quantified using a lactate assay kit (BioVision). Total secretion was calculated by subtracting results baseline lactate concentration, measured in samples from media incubated in identical conditions, without cells. Lactate production was normalized to cell count and data were expressed as percentage of control treated cells.
Standardization and Validation
Calibration samples were prepared by adding varying amounts of metformin or phenformin to blank plasma and to untreated tissue homogenate, respectively. Concentration range was from 5 pmol to 5000 pmol per 25 ml of plasma or tissue homogenate for metformin and from 0.5 pmol to 500 pmol for phenformin. Calibration samples were worked up as described above, and analyzed together with the unknown samples. Calibration curves based on internal standard calibration were obtained by weighted (1/x) linear regression for the peak-area ratio of the analyte to the respective internal standard against the amount of the analyte. The concentration in unknown samples was obtained from the regression line. Assay accuracy and precision were determined by analyzing quality controls that were prepared like the calibration samples.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using 2-way ANOVA (Prism; Graphpad), unless otherwise specified. Technical replicates were averaged prior to statistical analysis; statistics were calculated by comparing 2-3 independent experiments each consisting of the averaged technical replicate result, and data was expressed as mean ± SD of data from independent experiments. Details on data quantification, presentation and statistical analysis specific for each experimental method are included in their respective STAR Methods sections, and in the figure legends. 
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